--- page 1 ---
Graph Association Analyses for Early Drug Discovery
Wenfei Fanâˆ—
Shenzhen Institute of Computing
Sciences, China
University of Edinburgh, UK
Beihang University, China
wenfei@inf.ed.ac.ukDaji Li
Peiyu Liang
Shenzhen Institute of Computing
Sciences, China
lidaji@sics.ac.cn
liangpeiyu@sics.ac.cnShuhao Liu
Yaoshu Wang
Shenzhen Institute of Computing
Sciences, China
shuhao@sics.ac.cn
yaoshuw@sics.ac.cn
Yiming Wang
Shenzhen Institute of Computing
Sciences, China
wangyiming@sics.ac.cnMin Xie
Shenzhen Institute of Computing
Sciences, China
xiemin@sics.ac.cnRunjie Zhang
Shenzhen Institute of Computing
Sciences, China
zhangrunjie@sics.ac.cn
ABSTRACT
We demonstrate MedHunter , a system for assisting the early stage
of drug development. MedHunter builds a biomedical knowledge
graph DDKG by integrating data from eleven biochemical libraries
and data banks, and aligning entities from different data sources
by means of heterogeneous entity resolution. It identifies drug-
disease associations and protein-protein interactions in DDKG by
employing graph association rules ( GARs ).GARs use graph pat-
terns to extract relevant entities and embed ML models as predi-
cates. MedHunter discovers GARs from DDKG and incrementally
enriches DDKG with external data; it cleans DDKG with a special
form of GARs . We demonstrate MedHunter for its (a) interfaces,
(b) data enrichment/cleaning, and (c) applications in target identifi-
cation, drug-drug interaction and protein-protein interaction.
PVLDB Reference Format:
Wenfei Fan, Daji Li, Peiyu Liang, Shuhao Liu, Yaoshu Wang, Yiming Wang,
Min Xie, and Runjie Zhang. Graph Association Analyses for Early Drug
Discovery. PVLDB, 17(12): 4293 - 4296, 2024.
doi:10.14778/3685800.3685858
1 INTRODUCTION
Drug discovery is the process of new drug identification, starting
from target selection and validation, through preclinical screening,
to clinical trials [ 13]. It is time-consuming and costly. The develop-
ment of a new drug takes 10â€“15 years, costs around 2 billion US
dollars, and typically has a high risk of failure (>90%) [22].
To accelerate drug discovery, reduce the cost and increase the
success rate, machine learning (ML) models have been explored to
identify drug-disease associations (DDAs), drug-drug interactions
(DDIs), and protein-protein interactions (PPIs). However, it is costly
to train accurate deep-learning models, and ML predictions often
have false positives (FPs) and false negatives (FNs). Moreover, ML
predictions â€œstill lack reliable explanations that are crucial to drug
âˆ—Author names are listed in alphabetical order.
This work is licensed under the Creative Commons BY-NC-ND 4.0 International
License. Visit https://creativecommons.org/licenses/by-nc-nd/4.0/ to view a copy of
this license. For any use beyond those covered by this license, obtain permission by
emailing info@vldb.org. Copyright is held by the owner/author(s). Publication rights
licensed to the VLDB Endowment.
Proceedings of the VLDB Endowment, Vol. 17, No. 12 ISSN 2150-8097.
doi:10.14778/3685800.3685858repurposing and ADR (adverse drug reaction)â€ [ 22]. Worse yet,
noise is introduced by â€œunavoidable inaccuracyâ€ of the models, e.g.,
nonexistent relations and inaccurately named entities.
Can we do better? Is it possible to develop a cost-effective method
to reduce false positives and false negatives of ML predictions, and
moreover, enrich and clean the data from different data sources?
MedHunter (Section 2). In response to this, we have developed
a system to assist early drug discovery, known as MedHunter [1].
MedHunter aims to assist (1) target identification, to identify the
right biological molecules or cellular pathways that can be modu-
lated by drugs to achieve therapeutic benefits, in which PPIs are
often needed, (b) drug repurposing, to reuse existing drugs for a
new disease, and (c) ADR, to disclose undesirable impacts of drugs.
The need for these is evident. As an example, target identifica-
tion is perhaps the most crucial initial step in drug discovery, and
influences the chances of success at every step of drug development.
Traditional target identification easily takes from years to decades.
MedHunter helps select candidate targets and speed up the process.
Compared to ML models, MedHunter offers the following.
Graph association .MedHunter infers DDAs and DDIs from graphs
based on both ML predictions and logic deduction. It employs a class
of graph association rules ( GARs ) of the form ğ‘„[Â¯ğ‘¥](ğ‘‹â†’ğ‘0)[10].
Hereğ‘„is a graph pattern to extract related entities and their rela-
tionships/interactions; and ğ‘‹â†’ğ‘0is a dependency on the entities.
Moreover, ML models may be embedded as predicates for link/node
classification. This allows MedHunter to directly leverage existing
ML models, and enhance their predictions with logical reasoning.
Accuracy and explanation .MedHunter deduces association ğ‘0as a
logical consequence of GARs with certainty [ 12], using accumulated
ground truth, i.e.,if the GARs and ground truth are correct, so is ğ‘0.
Moreover, it filters FPs and FNs of ML model Mby adding logic
predicates in precondition ğ‘‹. A PPI deduced by MedHunter in May
2022 coincides a finding published in Nature in the same month [ 17].
In addition, if ğ‘0is an ML modelMfor predicting DDIs, DDAs,
PPIs or ADR, we can discover pattern ğ‘„and conditions ğ‘‹for rules
of the form ğ‘„[Â¯ğ‘¥](ğ‘‹â†’M) to provide rational behind the predic-
tions ofM. This is possible for GNN-based models, which are no
more expressive than two-variable first-order logic with limited
counting [ 6,14]. Such interpretability is one of the key advantages
ofMedHunter . It enables researchers to get a glimpse of the inner
4293

--- page 2 ---
workings ofM, so as to make improvement with novel insights.
A uniform KG .MedHunter builds DDKG , a drug-disease knowl-
edge graph (KG) in which it discovers GARs and deduces DDAs,
DDIs and PPIs. DDKG consists of data from eleven libraries and data
banks, e.g.,CTD [ 3] and BioGrid [ 2]. It aligns entities from different
graphs [ 9], and incrementally enriches DDKG by external data [ 11].
Biomedical data cleaning .MedHunter cleans DDKG by employing
a special form of GARs [7]. It (incrementally) discovers such GARs ,
detects errors and fixes the errors in DDKG with the GARs .
Demonstration (Section 3). We give a guided tour of MedHunter ,
from rule discovery, rule deduction of DDAs, DDIs and PPIs, to
aligned entities in DDKG . Participants are invited to interact with
MedHunter and experience how it helps in DDAs, DDIs and PPIs.
2 AN OVERVIEW OF MEDHUNTER
This sections presents the association rules (Section 2.1), knowledge
graph (Section 2.2) and architecture (Section 2.3) of MedHunter .
2.1 Graph Association Deduction
MedHunter employs graph association rules ( GARs ). Graphs are
modeled as ğº=(ğ‘‰,ğ¸,ğ¿,ğ¹ğ´), whereğ‘‰is a finite set of vertices;
ğ¸âŠ†ğ‘‰Ã—ğ¿(ğ¸)Ã—ğ‘‰is a finite set of edges (ğ‘£,ğ‘™,ğ‘£â€²)with labelğ‘™; eachğ‘£
inğ‘‰is labeled with its â€œcontentâ€ ğ¿(ğ‘£); and each vertex ğ‘£âˆˆğ‘‰carries
a tupleğ¹ğ´(ğ‘£)=(ğ´1=ğ‘1,...,ğ´ğ‘›=ğ‘ğ‘›)ofattributes of a finite arity.
GARs .GARs are defined with a pattern and a dependency. A graph
pattern isğ‘„[Â¯ğ‘¥]= (ğ‘‰ğ‘„,ğ¸ğ‘„,ğ¿ğ‘„,ğœ‡), where (1) ğ‘‰ğ‘„(resp.ğ¸ğ‘„) is a
finite set of vertices (resp. edges), (2) ğ¿ğ‘„assigns a label ğ¿ğ‘„(ğ‘¢)
(resp.ğ¿ğ‘„(ğ‘’)) to each pattern vertex ğ‘¢âˆˆğ‘‰ğ‘„(resp. edgeğ‘’âˆˆğ¸ğ‘„), (3)
Â¯ğ‘¥is a list of distinct variables, and ğœ‡is a bijective mapping from Â¯ğ‘¥to
ğ‘‰ğ‘„,i.e.,it assigns a distinct variable to each vertex ğ‘£inğ‘‰ğ‘„. Forğ‘¥âˆˆÂ¯ğ‘¥,
we useğœ‡(ğ‘¥)andğ‘¥interchangeably when it is clear in the context.
Amatch of patternğ‘„[Â¯ğ‘¥]in graphğºis a homomorphism â„from
ğ‘„toğºsuch that (a) for each ğ‘¢âˆˆğ‘‰ğ‘„,ğ¿ğ‘„(ğ‘¢)=ğ¿(â„(ğ‘¢)); and (b) for
eachğ‘’=(ğ‘¢,ğ‘™,ğ‘¢â€²)inğ‘„,ğ‘’â€²=(â„(ğ‘¢),ğ‘™,â„(ğ‘¢â€²))is an edge in ğº.
Apredicate of patternğ‘„[Â¯ğ‘¥]is one of the following:
ğ‘::=ğ‘™(ğ‘¥,ğ‘¦)|ğ‘¥.ğ´âŠ—ğ‘¦.ğµ|ğ‘¥.ğ´âŠ—ğ‘|2WLğ¿(ğ‘¥,ğ‘¦,ğ‘™)|M(ğ‘¥.Â¯ğ´,ğ‘¦. Â¯ğµ),
whereâŠ—is one of =,â‰ ,<,â‰¤,>,â‰¥;ğ‘¥andğ‘¦are variables in Â¯ğ‘¥;ğ‘is a
constant;ğ´andğµare attributes; and ğ‘¥.Â¯ğ´is a list of attributes at
â€œvertexâ€ğ‘¥; similarly for ğ‘¦.Â¯ğµ. We support (a) link predicate ğ‘™(ğ‘¥,ğ‘¦),
indicating the existence of an edge labeled ğ‘™from vertex ğ‘¥toğ‘¦; (b)
attribute predicates ğ‘¥.ğ´âŠ—ğ‘¦.ğµandğ‘¥.ğ´âŠ—ğ‘to compare attribute values;
(c)2WLğ¿(ğ‘¥,ğ‘¦,ğ‘™), to check whether there is a link of â€œtypeâ€ (label) ğ‘™
fromğ‘¥toğ‘¦by local 2-WL (Weisfieler-Leman) test [ 15] (see below);
and (d) ML predicateM(ğ‘¥.Â¯ğ´,ğ‘¦. Â¯ğµ)returns true iffMpredicts true at
(ğ‘¥.Â¯ğ´,ğ‘¦. Â¯ğµ); hereMis an ML model that returns Boolean ( e.g.,Mâ‰¥
ğœif the strength of the Mprediction is above a predefined bound ğœ).
Agraph association rule (GAR )ğœ‘is defined as
ğ‘„[Â¯ğ‘¥](ğ‘‹â†’ğ‘0),
whereğ‘„[Â¯ğ‘¥]is a graph pattern, ğ‘‹is a (possibly empty) conjunction
of predicates of ğ‘„[Â¯ğ‘¥], andğ‘0is a predicate of ğ‘„[Â¯ğ‘¥]. We refer to
ğ‘„[Â¯ğ‘¥]andğ‘‹â†’ğ‘0as the pattern anddependency ofğœ‘, respectively,
and toğ‘‹andğ‘0as the precondition andconsequence , respectively.
Intuitively, the pattern ğ‘„extracts related entities in a graph,
and the dependency ğ‘‹â†’ğ‘0is applied to the entities. Attribute
Figure 1: Graph patterns in GARs
predicatesğ‘¥.ğ´=ğ‘andğ‘¥.ğ´=ğ‘¦.ğµspecify value associations of
attributes, and link predicates ğ‘™(ğ‘¥,ğ‘¦)make link associations . One can
â€œplug inâ€ pre-trained ML models Mfore.g.,ER and classification.
Predicate 2WLğ¿(ğ‘¥,ğ‘¦,ğ‘™)is used to explain the predictions of M.
As shown in [ 15], most GNN models for link prediction are based
on the 1-WL test, and are at most as expressive as local 2-WL test.
Thus with 2WLğ¿(ğ‘¥,ğ‘¦,ğ‘™),GARs can explain such GNN predictions.
Below we exemplify GARs discovered from real-life data.
(1) Drug repurposing . Upon the request of our biomedical partners,
MedHunter was used to discover GARs for repositioning of existing
drugs on a type of Parkinson disease. A GAR isğœ‘1=ğ‘„1[Â¯ğ‘¥](ğ‘‹1â†’
ğ‘™(ğ‘¥0,ğ‘¥1))in Figure 1. The rule is discovered from CTD [ 3]. Together
withğ‘„1, precondition ğ‘‹1specifies the following: (1) drug ğ‘¥0has a
known effect on an inborn genetic blood disease ğ‘¥2; (2) diseaseğ‘¥1is
the Parkinson; (3) drug ğ‘¥0interacts with a gene ğ‘¥3, which shares an
effect pathway ğ‘¥4withğ‘¥1; (4) drugğ‘¥0can interact with a gene ğ‘¥5,
which has anM1-predicted relationship with ğ‘¥1(the dashed arrow
inğ‘„1), whereM1is a model that predicts the associations between
genes and diseases [ 18,20,21]; and (5) drug ğ‘¥0has a known effect
on a type of skin cancer ğ‘¥6, which shares an effect pathway with
ğ‘¥1. The predicted link ğ‘™(ğ‘¥0,ğ‘¥1)(the bold line in ğ‘„1) indicates that
drugğ‘¥0may be associated to Parkinsonâ€™s disease ğ‘¥1in some way.
Such GARs found five drugs for Parkinson, four with published
evidence and the remaining one is under lab investigation.
(2) Protein-protein interaction .BioGRID [2] is a popular biomedical
repository. After enriching it with external data, e.g.,UniProt [5], a
GAR isğœ‘2=ğ‘„2[Â¯ğ‘¥](M 2(ğ‘¥0,ğ‘¥0)â‰¥ğ›¿âˆ§ğ‘‹2â†’ğ‘™(ğ‘¥0,ğ‘¥0)), in whichM2
is aRGCN model [ 19] for PPIs,ğ‘„2is given in Figure 1 in which each
vertex (resp. edge) denotes a protein (resp. PPI); here ğ‘‹2specifies
logic conditions e.g.,the domains and subcellular locations. This
GAR identifies the self-interaction ğ‘™(ğ‘¥0,ğ‘¥0)(the bold loop in ğ‘„2) on
ğ‘¥0by filtering the FPs of the prediction of M2with additional logic
conditions in ğ‘‹2,i.e.,although the strength of the M2prediction is
above the threshold ğ›¿, the prediction is made only if ğ‘‹2holds.
A PPI identified by such GARs coincides a finding in [17].
(3) Explanation . Ifğ‘0is an ML predicate, MedHunter can discover
GARs to explain the ML prediction, e.g.,ğœ‘3=ğ‘„3[Â¯ğ‘¥](ğ‘‹3â†’M 3(ğ‘¥0,
ğ‘¥4))in Figure 1, where M3is an ML model that predicts the in-
teraction between gene ğ‘¥0and disease ğ‘¥4. This GAR explains why
M3(ğ‘¥0,ğ‘¥4)is true (the bold line in ğ‘„3) with bothğ‘„3andğ‘‹3,i.e.,(1)
geneğ‘¥0has interacted with pathway ğ‘¥2; (2) geneğ‘¥0has interacted
with disease ğ‘¥1that has also interacted with pathway ğ‘¥3; (3) geneğ‘¥5
is predicted to interact with pathway ğ‘¥3by2WLğ¿, and it has effect
on diseaseğ‘¥4; and (4) pathway ğ‘¥2has effect on diseases ğ‘¥1andğ‘¥4.
4294

--- page 3 ---
NCBI MeSH KEGG
STRINGCTD
REACTOME OMIMPharmGKB
BioGRIDGene OntologyData SourcesHeterogeneous entity 
resolutionGraph join Graph filteringData EnrichmentFunctionality
Rule discoveryBatch and 
Incremental Data cleaning Rule deductionDurg-disease 
associationDrug-drug interactionProtein-protein 
interactionApplicationsUser Intersaction
UniProt ClustalW DAVIDFigure 2: The architecture of MedHunter
 Figure 3: A snapshot of the user panel of MedHunter
Algorithms .MedHunter implements (a) the algorithm of [ 8] for
discovering GARs , (b) an extension of [ 12] for deducing missing
DDIs, DDAs and PPIs; it chases a biomedical graph with a set Î£of
mined GARs by accumulating and referencing ground truth in the
process. Both algorithms are parallely scalable, i.e.,they provably
guarantee to reduce runtime when given more processors [16].
2.2 Cleaning and Enriching DDKG
MedHunter maintains DDKG by enriching and cleaning its data.
Drug-Disease Knowledge Graph .DDKG integrates biomedical
libraries and data banks, by computing their join as follows.
MedHunter aligns entities across different graphs by employing
heterogeneous entity resolution ( HER ) [9]. For a vertex ğ‘£1in graph
ğº1and vertexğ‘£2in another graph ğº2, it determines whether ğ‘£1
andğ‘£2refer to the same entity via parametric simulation, which
embeds ML models for similarity checking in topological matching.
Givenğº1=(ğ‘‰1,ğ¸1,ğ¿1,ğ¹1)andğº2=(ğ‘‰2,ğ¸2,ğ¿2,ğ¹2),MedHunter
â€œjoinsâ€ them as ğºâŠ•(ğº1,ğº2)=(ğ‘‰âŠ•,ğ¸âŠ•,ğ¿âŠ•,ğ¹âŠ•), whereğ‘‰âŠ•(resp.ğ¸âŠ•)
is a revision of the union ğ‘‰1âˆªğ‘‰2(resp.ğ¸âˆªğ¸2) such thatğ‘¢andğ‘£are
represented as the same (merged) vertex in ğ‘‰âŠ•if(ğ‘¢,ğ‘£)is a match
byHER ; andğ¿âŠ•andğ¹âŠ•inherit the label and attribute assignments
fromğº1andğº2. Whenğ‘¢andğ‘£both carry attribute ğ´, the merged
vertex takes the value ğ‘£.ğ´from more reliable ğºğ‘–(âˆˆ[1,2]).
Data enrichment . To ensure that DDKG remains up-to-date and
relevant, MedHunter continuously and incrementally enriches it in
response to updates Î”ğºto the source graphs. Rather than adding
all data from Î”ğº, it employs the graph filtering method of [ 11]
to extract only relevant data to DDKG ; it applies LSTM to pick
â€œimportantâ€ paths ranks the paths, extracts data from top-ranked
paths, and enriches DDKG with the data. As shown in [ 11], graph
filtering is effective in reducing noise and the size of DDKG .
Data cleaning .MedHunter maintains the quality of DDKG via
a (human-in-the-loop) cleaning procedure, using a special case of
GARs , referred to as Graph Cleaning Rules ( GCRs ) [7]. AGCR has a
formQ[ğ‘¥0,ğ‘¦0](ğ‘‹â†’ğ‘0), whereQ[ğ‘¥0,ğ‘¦0]=âŸ¨ğ‘„ğ‘¥[ğ‘¥0,Â¯ğ‘¥],ğ‘„ğ‘¦[ğ‘¦0,Â¯ğ‘¦]âŸ©,
ğ‘„ğ‘¥[ğ‘¥0,Â¯ğ‘¥]is a star shape pattern with a designed ğ‘¥0; similarly for
ğ‘„ğ‘¦[ğ‘¦0,Â¯ğ‘¦].GCRs support all the predicates of GARs except 2WLğ¿.
Intuitively,Qspecifies two entities ğ‘¥0andğ‘¦0with heterogeneous
structures in a schemaless graph. The star patterns identify features
ofğ‘¥0andğ‘¦0. We restrict ğ‘„ğ‘¥andğ‘„ğ‘¦to a star shape so that it takes
polynomial time to check matches of such Q, and to apply GCRs [7].
MedHunter automatically discovers GCRs from DDKG . To cleandata with certain fixes, users can selectively apply a set of GCRs
based on labeled ground-truth data; they may optionally intervene
in a prompt-and-confirm style to facilitate the cleaning process.
Algorithms .MedHunter implements (a) the algorithms of [ 11] for
graph join, data enrichment, and incremental discovery of GARs ;
(b) the algorithms of [ 7] for mining GCRs and detecting errors;
and (c) an extension of the algorithm of [ 12] for fixing the detected
errors. All the algorithms are also parallelly scalable [16].
2.3 The Architecture of MedHunter
The architecture of MedHunter is shown in Figure 2. It consists of
the following main modules, from the bottom to the top.
â—¦Data sources , which maintain raw data from various libraries and
data banks. New data can be dynamically merged with DDKG .
â—¦Data enrichment . On top of the data source module, MedHunter
conducts data enrichment, by first aligning entities across differ-
ent sources and then leveraging graph join and graph filtering
techniques to construct a unified knowledge graph DDKG .
â—¦Rule discovery and data cleaning . Based on the integrated DDKG ,
MedHunter supports GAR /GCR discovery, cleaning and associ-
ation deduction, in both batch and incremental modes. before.
â—¦Applications . The GARs discovered are then used in various
biomedical applications, for identifying DDAs, DDIs and PPIs,
3 DEMONSTRATION SETUP AND PLAN
This section proposes our plan for demonstrating MedHunter1.
Setup . We will use a single machine powered by 16GB RAM and 8
processors with Intel(R) Xeon(R) Gold 5320 CPU @2.20GH.
User interface . Participants are invited to access MedHunter from
its Web UI. As shown in the snapshot of Figure 3, MedHunter
presents a friendly interface. The top navigation bar provides access
to three main modules of MedHunter . Each module is task-based,
and it takes only a few clicks to get a task up and running. We
will walk users through the process of creating new tasks, where
they configure inputs and monitor its progress. The task results are
visualized and updated in real time through the dashboard.
Data enrichment . We will give a guided tour of how MedHunter
enriches DDKG from external data, e.g.,PharmGKB [ 4]. User can
â€œjoinâ€ data and DDKG , and take the enriched DDKG for further anal-
ysis. The process is interactive and visualized on the Web interface.
1https://youtu.be/rhvcXBjtLhw
4295

--- page 4 ---
1. disease3. variant
Variant Annotation count: 
(Variant Annotation count<125)
             2. chemical
VIP Count: (VIP Countâ‰¥3)
0. variantc-vc-v
d-vd-v
c-d1. disease
ARTIVILA Id: PA445742
0. variant
Clinical Annotation count: 0
Gene Symbols: IGFBP3
3. variant
Clinical Annotation count: 1
Gene Symbols: VEGFA
              2. chemical
ARTIVILA Id: PA128406956
Brand Mixtures: 5FUc-vd-v
c-dc-vd-vFigure 4: MedHunter in DDAs
Data cleaning . We will walk users through the data cleaning pro-
cess of MedHunter . We will guide users to configure and run rule
discovery for GCRs . The users can examine the discovered GCRs ,
and pick a subset for cleaning. We will demonstrate interactive data
cleaning, using the selected GCRs . During the process, MedHunter
will visualize detected errors and the GCRs , with suggested fixes. A
user may opt to either accept a suggestion or customize a fix, which
will be taken as ground truth for subsequent GCR applications.
Applications . Participants are also invited to experience drug
discovery with MedHunter , in the following three scenarios. Each
scenario is offered as a task template under rule discovery.
Scenario 1: DDAs . Users may pick a disease ğ‘¦, and identify either
(a) molecule targets or (b) existing drugs that may have therapeutic
effects on the disease. It is to discover and apply GARs whose
consequence has the form ğ‘™(ğ‘¥,ğ‘¦), whereğ‘¥is a drug or a gene. Over
DDKG , we will direct users to specify ğ‘¦in the task template for
GAR discovery and monitor its execution. The discovered GARs
and their predicted DDAs are visualized and updated in real time.
A learned GARğœ‘4=ğ‘„4[Â¯ğ‘¥](ğ‘¥2.NVIPâ‰¥3âˆ§ğ‘¥3.Nanno<125â†’
ğ‘™(ğ‘¥2,ğ‘¥1))is shown in the left panel of Figure 4. It suggests that a
drugğ‘¥2may be associated to disease ğ‘¥1, provided that (1) ğ‘¥2has a
high VIP count ( i.e.,an active compound), and (2) ğ‘¥1andğ‘¥2both
interact with a gene variant ğ‘¥3that has a low annotation count
(<125).MedHunter reports that GARğœ‘4has a support of 51, with
confidence over 0.95. One of its predicted DDAs is between Drug
#PA128406956 and Disease #PA445742 (shown in the right panel).
Scenario 2: DDIs .MedHunter can also disclose drug-drug interac-
tions. We will demonstrate this functionality in a procedure similar
to DDAs, except that it allows users to specify a target drug as ğ‘¦.
Scenario 3: PPIs . The participants will also witness how MedHunter
identifies protein-protein interactions. It is to discover and apply
link predicting GARs over the PPI network of DDKG , along with
ML models for PPI predictions, e.g.,RGCN. We will guide the users
to examine the result as GARs focus on reducing the FPs and FNs.
Figure 5 shows a discovered GARğœ‘5=ğ‘„5[Â¯ğ‘¥](ğ‘¥1.pathway =
Metabolism _of_proteinsâˆ§ğ‘¥1.domain =Cyclinâˆ§M 2(ğ‘¥1,ğ‘¥1)=
falseâ†’ğ‘™(ğ‘¥1,ğ‘¥1)). The ruleâ€™s confidence is 0.993; it suggests the self-
PPI on protein ğ‘¥1despite the negative prediction of M2, if (1) Cyclin-
domainğ‘¥1is involved in the pathway â€œMetabolism of proteinsâ€,
and (2)ğ‘¥1shares at least two common PPIs with protein ğ‘¥2.
0. protein 3. protein
2. proteinp-p
p-p p-pp-pp-p1. protein
domain: PF00134,PF02984
location: Nucleus
3. protein
domain: PF00069
location: Cytoplasm,
Nucleus
2. protein
domain: PF00653
location: Cytoplasm,Nucleusp-p
p-p
p-pp-p
0. protein
domain: 
PF00069,PF00169,PF00433
location: Cytoplasm,
1. protein
pathway: Metabolism of proteins
domain: Â¬(PF02752,PF00339)
p-pFigure 5: MedHunter in PPIs
We will show that MedHunter reduces the FPs and FNs of ML
models for these tasks, by improving the precision by 4%on average.
ACKNOWLEDGMENTS
This work is supported by China NSFC 62202313 and Guangdong
Basic and Applied Basic Research Foundation 2022A1515010120.
REFERENCES
[1]2024. AI-based Drug Development Solution. https://www.grandhoo.com/en/
fishtown/product-solution/qubing/.
[2] 2024. BioGRID. https://thebiogrid.org/.
[3] 2024. Comparative Toxicogenomics Database (CTD). https://ctdbase.org/.
[4] 2024. PharmGKB dataset. https://www.pharmgkb.org/.
[5] 2024. UniProt. https://www.uniprot.org/.
[6] Jin-yi Cai, Martin FÃ¼rer, and Neil Immerman. 1992. An optimal lower bound on
the number of variables for graph identification. Comb. 12, 4 (1992), 389â€“410.
[7] Wenfei Fan, Wenzhi Fu, Ruochun Jin, Muyang Liu, Ping Lu, and Chao Tian. 2023.
Making It Tractable to Catch Duplicates and Conflicts in Graphs. Proc. ACM
Manag. Data 1, 1 (2023), 86:1â€“86:28.
[8] Wenfei Fan, Wenzhi Fu, Ruochun Jin, Ping Lu, and Chao Tian. 2022. Discovering
Association Rules from Big Graphs. PVLDB 15, 7 (2022), 1479â€“1492.
[9]Wenfei Fan, Ling Ge, Ruochun Jin, Ping Lu, and Wenyuan Yu. 2022. Linking
Entities across Relations and Graphs. In ICDE . IEEE, 634â€“647.
[10] Wenfei Fan, Ruochun Jin, Muyang Liu, Ping Lu, Chao Tian, and Jingren Zhou.
2020. Capturing Associations in Graphs. PVLDB 13, 11 (2020), 1863â€“1876.
[11] Wenfei Fan, Muyang Liu, Shuhao Liu, and Chao Tian. 2024. Catching More
Associations by Referencing Knowledge Graphs. PVLDB (2024).
[12] Wenfei Fan, Ping Lu, Chao Tian, and Jingren Zhou. 2019. Deducing Certain Fixes
to Graphs. PVLDB 12, 7 (2019), 752â€“765.
[13] Chris Fotis, Asier Antoranz, Dimitris Hatziavramidis, Theodore Sakellaropoulos,
and Leonidas G. Alexopoulos. 2017. Pathway-based technologies for early drug
discovery. Drug Discovery Today (2017).
[14] Martin Grohe. 2020. word2vec, node2vec, graph2vec, X2vec: Towards a Theory
of Vector Embeddings of Structured Data. In PODS . ACM, 1â€“16.
[15] Yang Hu, Xiyuan Wang, Zhouchen Lin, Pan Li, and Muhan Zhang. 2022. Two-
Dimensional Weisfeiler-Lehman Graph Neural Networks for Link Prediction.
CoRR abs/2206.09567 (2022).
[16] Clyde P. Kruskal, Larry Rudolph, and Marc Snir. 1990. A complexity theory of
efficient parallel algorithms. Theor. Comput. Sci. 71, 1 (1990), 95â€“132.
[17] Ying Lai, Giorgio Fois, Jose R Flores, et al .2022. Inhibition of calcium-triggered
secretion by hydrocarbon-stapled peptides. Nature 603, 7903 (2022), 949â€“956.
[18] Yu Li, Hiroyuki Kuwahara, Peng Yang, Le Song, and Xin Gao. 2019. PGCN:
Disease gene prioritization by disease and gene embedding through graph con-
volutional neural networks. biorxiv (2019), 532226.
[19] Michael Schlichtkrull, Thomas N Kipf, Peter Bloem, Rianne Van Den Berg, Ivan
Titov, and Max Welling. 2018. Modeling relational data with graph convolutional
networks. In The Semantic Web (ESWC) . Springer, 593â€“607.
[20] Juan Shu, Yu Li, Sheng Wang, Bowei Xi, and Jianzhu Ma. 2021. Disease gene pre-
diction with privileged information and heteroscedastic dropout. Bioinformatics
37, Supplement_1 (2021), i410â€“i417.
[21] Xiaochan Wang, Yuchong Gong, Jing Yi, and Wen Zhang. 2019. Predicting gene-
disease associations from the heterogeneous network using graph embedding. In
IEEE International conference on bioinformatics and biomedicine (BIBM) . 504â€“511.
[22] Xiangxiang Zeng, Xinqi Tu, Yuansheng Liu, Xiangzheng Fu, and Yansen Su.
2022. Toward better drug discovery with knowledge graph. Current opinion in
structural biology 72 (2022), 114â€“126.
4296